METHODS OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS

(19)

(11)

EP 2 349 282 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	26.02.2020 Bulletin 2020/09

(45)	Mention of the grant of the patent:
	15.01.2020 Bulletin 2020/03

(21)	Application number: 09821103.0

(22)	Date of filing: 13.10.2009

(51)

International Patent Classification (IPC):

A61K 31/7036^(2006.01)
A61K 9/127^(2006.01)
A61P 11/12^(2006.01)
A61K 9/00^(2006.01)
A61K 31/70^(2006.01)

A61P 11/00^(2006.01)
A61K 47/44^(2017.01)
A61P 31/04^(2006.01)
A61K 31/375^(2006.01)

(86)	International application number:
	PCT/US2009/060468

(87)	International publication number:
	WO 2010/045209 (22.04.2010 Gazette 2010/16)

(54)	METHODS OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS VERFAHREN ZUR BEHANDLUNG VON LUNGENERKRANKUNGEN MIT LIPOSOMALEN AMIKACINFORMULIERUNGEN PROCÉDÉS DE TRAITEMENT DE TROUBLES PULMONAIRES PAR DES FORMULATIONS LIPOSOMALES D'AMIKACINE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)

Priority:

13.10.2008 US 250412

(43)	Date of publication of application:
	03.08.2011 Bulletin 2011/31

(73)	Proprietor: Insmed Incorporated
	Bridgewater, NJ 08807-1704 (US)

(72)	Inventor:
	GUPTA, Renu Moorestown, NJ 08057 (US)

(74)	Representative: CMS Cameron McKenna Nabarro Olswang LLP
	Cannon Place 78 Cannon Street London EC4N 6AF London EC4N 6AF (GB)

(56)

References cited: :

US-A1- 2008 131 497

MEERS P ET AL: "Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, OXFORD UNIVERSITY PRESS, GB, vol. 61, no. 4, 1 April 2008 (2008-04-01), pages 859-868, XP002632705, ISSN: 0305-7453, DOI: 10.1093/JAC/DKN059 [retrieved on 2008-02-27]
RAMSEY B W ET AL: "INTERMITTENT ADMINISTRATION OF INHALED TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 340, no. 1, 7 January 1999 (1999-01-07), pages 23-30, XP001106341, ISSN: 0028-4793, DOI: 10.1056/NEJM199901073400104
CLANCY J P ET AL: "Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.", THORAX SEP 2013, vol. 68, no. 9, September 2013 (2013-09), pages 818-825, XP002742980, ISSN: 1468-3296

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).